Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Since the dramatic rise of the coronavirus infection disease 2019 (COVID-19) pandemic, patients receiving dialysis have emerged as especially susceptible to this infection because of their impaired immunologic state, chronic inflammation and the high incidence of comorbidities. Although several strategies have thus been implemented to minimize the risk of transmission and acquisition in this population worldwide, the reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence varies across studies but is higher than in the general population. On the contrary, the screening for hepatitis viruses (HBV and HCV) has seen significant improvements in recent years, with vaccination in the case of HBV and effective viral infection treatment for HCV. In this sense, a universal SARS-CoV-2 screening and contact precaution appear to be effective in preventing further transmission. Finally, regarding the progress, an international consensus with updated protocols that prioritize between old and new indicators would seem a reasonable tool to address these unexpended changes for the nephrology community.

Details

Title
SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?
Author
Luis D’Marco 1   VIAFID ORCID Logo  ; María Jesús Puchades 1   VIAFID ORCID Logo  ; Serra, Miguel Ángel 2 ; Gandía, Lorena 3 ; Romero-Alcaide, Sergio 3 ; Giménez-Civera, Elena 3 ; Molina, Pablo 4 ; Panizo, Nayara 1 ; Reque, Javier 5   VIAFID ORCID Logo  ; Gorriz, José Luis 1   VIAFID ORCID Logo 

 Nephrology Department, Hospital Clínico Universitario (INCLIVA), 46010 Valencia, Spain; [email protected] (M.J.P.); [email protected] (L.G.); [email protected] (S.R.-A.); [email protected] (E.G.-C.); [email protected] (N.P.); School of Medicine, Universidad de Valencia, 46010 Valencia, Spain; [email protected] (M.Á.S.); [email protected] (P.M.) 
 School of Medicine, Universidad de Valencia, 46010 Valencia, Spain; [email protected] (M.Á.S.); [email protected] (P.M.); Digestive Medicine Department, Hospital Clínico Universitario de Valencia, 46010 València, Spain 
 Nephrology Department, Hospital Clínico Universitario (INCLIVA), 46010 Valencia, Spain; [email protected] (M.J.P.); [email protected] (L.G.); [email protected] (S.R.-A.); [email protected] (E.G.-C.); [email protected] (N.P.) 
 School of Medicine, Universidad de Valencia, 46010 Valencia, Spain; [email protected] (M.Á.S.); [email protected] (P.M.); Nephrology Department, Hospital Dr. Peset, FISABIO, 46017 València, Spain 
 Nephrology Department, Hospital de Castellón, 12004 Castellón, Spain; [email protected] 
First page
5748
Publication year
2021
Publication date
2021
Publisher
MDPI AG
ISSN
1661-7827
e-ISSN
1660-4601
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2539735136
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.